Bispecific Antibodies: The Next Generation of Antibody Therapeutics

Within the past 3 years alone, the FDA has approved 20 novel antibody therapeutics for oncological treatment, with over 300 therapeutic antibodies currently in oncology based clinical trials . However, despite this exponential growth, most therapeutic antibodies rely on a monomeric immunotherapy based mechanism. Therefore, there is an urgent demand for new therapeutic strategies, such as combinatorial therapy, and novel modalities, such as bispecific antibodies.

Speaker Bio

Dr. Liusong Yin

Dr. Liusong Yin is the Director and Head of Antibody Department at GenScript USA Inc. Dr. Yin received his Ph.D. from the University of Massachusetts Medical School, specializing in antigen presentation, CD4+ T cell epitope selection, and antibody responses. Dr. Yin has extensive experience in Antibody drug discovery, he has published over 14 highly-cited papers in immunology, virology, and biochemistry Journals, and has received 5 patents in the antibody discovery field.

Related Services

Speaker-related Webinars

Identify the optimal protein purification strategy for your recombinant protein production

Are you challenged with obtaining sufficient amount of high purity proteins for your applications? Almost unavoidably, every protein purification step results in some degree of protein loss.

Learn More

Recombinant protein expression & purification

Are you struggling with the amount and/or purity of your recombinant protein? Attend this online seminar for solutions to the challenges in recombinant protein expression & purification.

Learn More

Accelerating Lead Identification Through Paramagnetic Bead Purification Technology

High throughput purification is a critical step in antibody engineering and lead identification. Paramagnetic bead technology allows a single step purification of targets by simply adding the beads directly

Learn More

Efficient stable cell pool/cell line development for large-scale antibody and protein production

Interested in rapid and efficient stable cell pool/cell line development for large-scale production of your recombinant antibodies and proteins? If so, this webinar may be for you.

Learn More

Chaperone co expression strategies for recombinant soluble protein production in E. Coli

Recombinant protein expression in E. coli often results in the formation of insoluble aggregates called inclusion bodies.

Learn More